Is Riluzole on the market?

The U.S. Food and Drug Administration (FDA) approved Riluzole for the treatment of amyotrophic lateral sclerosis (ALS) in 1995. It is marketed by Sanofi under the trade name Rilutek. A review pointed out that the probability of survival for one year increased by 9%. Riluzole is widely metabolized into six major metabolites and some minor metabolites, and these metabolites have not yet been fully identified.

Riluzole, a member of the benzothiazole class, prolongs survival and /or duration of tracheostomy surgery. It is also neuroprotective in various in vivo experimental models of neuronal injury involving excitotoxic mechanisms. The cause and pathogenesis of amyotrophic lateral sclerosis (ALS) are unknown, although many hypotheses have been proposed that motor neurons that are vulnerable due to genetic predisposition or environmental factors are damaged by glutamate, and in some familial ALS cases, superoxide dismutase defects have been found.

The original drug Riluzole has been launched in China and has entered the scope of Class B medical insurance. Specifications The price of 50mg*56 tablets per box may be around 4,000 RMB. The price of the Turkish version of Riluzole’s original drug, 50mg*56 tablets, sold overseas may be around RMB 1,200 per box (the price may fluctuate due to exchange rates). There are also generic drugs produced in other countries. The price of a box of 50mg*30 tablets produced by an Indian pharmaceutical factory may be around RMB 1,300 (the price may fluctuate due to the exchange rate). The pharmaceutical ingredients of generic drugs are basically the same as those of domestic and foreign original drugs. For specific prices and drug information, please consult Yaode Medical Consultants.